These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 30466755)
21. Can Minimal Residual Disease Determination in Acute Myeloid Leukemia Be Used in Clinical Practice? Luskin MR; Stone RM J Oncol Pract; 2017 Aug; 13(8):471-480. PubMed ID: 28796964 [TBL] [Abstract][Full Text] [Related]
22. Minimal/Measurable Residual Disease Monitoring in Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199 [TBL] [Abstract][Full Text] [Related]
23. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia. Buccisano F; Hourigan CS; Walter RB Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628 [TBL] [Abstract][Full Text] [Related]
24. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. Ehinger M; Pettersson L APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505 [TBL] [Abstract][Full Text] [Related]
25. Challenges of detecting measurable/minimal disease in acute leukemia. Zhang J; Oak J Semin Diagn Pathol; 2023 May; 40(3):216-220. PubMed ID: 37150656 [TBL] [Abstract][Full Text] [Related]
26. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. Pettit K; Stock W; Walter RB Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126 [TBL] [Abstract][Full Text] [Related]
27. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Appelbaum FR Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531 [TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162 [TBL] [Abstract][Full Text] [Related]
29. Minimal Residual Disease in Acute Myeloid Leukemia. Gomez-Arteaga A; Guzman ML Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263 [TBL] [Abstract][Full Text] [Related]
36. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571 [TBL] [Abstract][Full Text] [Related]
37. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957 [TBL] [Abstract][Full Text] [Related]
38. Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. Schwind S; Jentzsch M; Bach E; Stasik S; Thiede C; Platzbecker U Curr Treat Options Oncol; 2020 Jan; 21(1):8. PubMed ID: 32002673 [TBL] [Abstract][Full Text] [Related]
39. Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia. Chen X; Cherian S Clin Lab Med; 2021 Sep; 41(3):467-483. PubMed ID: 34304776 [TBL] [Abstract][Full Text] [Related]
40. Can we incorporate MRD assessment into clinical practice in AML? Ossenkoppele G; Schuurhuis GJ; van de Loosdrecht A; Cloos J Best Pract Res Clin Haematol; 2019 Jun; 32(2):186-191. PubMed ID: 31204000 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]